Dr. Prashant Dhirajlal Bhensdadia, MD

Dr. Bhensdadia practices at Atrium Health Cabarrus in Concord, North Carolina, part of Advocate Health.

Dr. Bhensdadia's NPI, 1336535822, was assigned on April 10, 2015. Dr. Bhensdadia holds North Carolina license 2018-01768.

Dr. Bhensdadia's primary practice is Atrium Health Cabarrus, at 920 Church St N, Concord, NC 28025 in Cabarrus County. The practice phone is (704) 783-3000.

Dr. Bhensdadia's primary practice is Atrium Health Cabarrus in Concord, North Carolina, part of Advocate Health. Dr. Bhensdadia is also affiliated with Atrium Health Carolinas Medical Center. The medical group on file is Atrium Health Cleveland Imaging. Dmand AI also links Dr. Bhensdadia to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bhensdadia practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Bhensdadia's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Bhensdadia is licensed in North Carolina.

CMS data shows 886 Medicare services from Dr. Bhensdadia across 7 procedure codes in 2024, for 329 Medicare patients. Medicare paid $81,314 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 329 Medicare patients who saw Dr. Bhensdadia in 2024. The largest group is 75 to 84, with 121 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 28% are also on Medicaid. Their average risk score is 2.24, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bhensdadia's median patient age at 74, with 53% women.

In 2024, Dr. Bhensdadia wrote 426 Medicare Part D claims for 223 patients. 88% of them were for generic drugs. CMS names the drug for 202 of them, across 9 drugs with 11 or more claims each, at $2,073 in total drug cost. In 2023, CMS named 158 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Bhensdadia for performance year 2024, reported through an alternative payment model (APM). Dr. Bhensdadia accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 7 general payments to Dr. Bhensdadia from 2 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 100% of the total. Allergan Inc. paid the most, $87.